These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 18160670)

  • 61. A higher JAK2 V617F-mutated clone is observed in platelets than in granulocytes from essential thrombocythemia patients, but not in patients with polycythemia vera and primary myelofibrosis.
    Bellosillo B; Martínez-Avilés L; Gimeno E; Florensa L; Longarón R; Navarro G; Salar A; Espinet B; Solé F; Serrano S; Besses C
    Leukemia; 2007 Jun; 21(6):1331-2. PubMed ID: 17361221
    [No Abstract]   [Full Text] [Related]  

  • 62. New insights into the pathogenesis of JAK2 V617F-positive myeloproliferative disorders and consequences for the management of patients.
    Villeval JL; James C; Pisani DF; Casadevall N; Vainchenker W
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):341-51. PubMed ID: 16810610
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Rapid identification of heterozygous or homozygous JAK2(V617F) mutations in myeloproliferative neoplasms using melting curve analysis.
    Ho CL; Wu YY; Hung HM; Chang PY; Kao WY; Chen YC; Chao TY
    J Formos Med Assoc; 2012 Jan; 111(1):34-40. PubMed ID: 22333011
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Polycythemia vera: the current status of preclinical models and therapeutic targets.
    Bartalucci N; Guglielmelli P; Vannucchi AM
    Expert Opin Ther Targets; 2020 Jul; 24(7):615-628. PubMed ID: 32366208
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
    Zhan H; Spivak JL
    Clin Adv Hematol Oncol; 2009 May; 7(5):334-42. PubMed ID: 19521323
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Hmga2 promotes the development of myelofibrosis in Jak2
    Dutta A; Hutchison RE; Mohi G
    Blood; 2017 Aug; 130(7):920-932. PubMed ID: 28637665
    [TBL] [Abstract][Full Text] [Related]  

  • 67. JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFNα.
    Hasan S; Lacout C; Marty C; Cuingnet M; Solary E; Vainchenker W; Villeval JL
    Blood; 2013 Aug; 122(8):1464-77. PubMed ID: 23863895
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.
    Michiels JJ; Berneman Z; Van Bockstaele D; van der Planken M; De Raeve H; Schroyens W
    Semin Thromb Hemost; 2006 Apr; 32(3):174-207. PubMed ID: 16673274
    [TBL] [Abstract][Full Text] [Related]  

  • 69. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.
    Pikman Y; Lee BH; Mercher T; McDowell E; Ebert BL; Gozo M; Cuker A; Wernig G; Moore S; Galinsky I; DeAngelo DJ; Clark JJ; Lee SJ; Golub TR; Wadleigh M; Gilliland DG; Levine RL
    PLoS Med; 2006 Jul; 3(7):e270. PubMed ID: 16834459
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders.
    Pietra D; Li S; Brisci A; Passamonti F; Rumi E; Theocharides A; Ferrari M; Gisslinger H; Kralovics R; Cremonesi L; Skoda R; Cazzola M
    Blood; 2008 Feb; 111(3):1686-9. PubMed ID: 17984312
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Clonal analysis of deletions on chromosome 20q and JAK2-V617F in MPD suggests that del20q acts independently and is not one of the predisposing mutations for JAK2-V617F.
    Schaub FX; Jäger R; Looser R; Hao-Shen H; Hermouet S; Girodon F; Tichelli A; Gisslinger H; Kralovics R; Skoda RC
    Blood; 2009 Feb; 113(9):2022-7. PubMed ID: 19047681
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Different STAT-3 and STAT-5 phosphorylation discriminates among Ph-negative chronic myeloproliferative diseases and is independent of the V617F JAK-2 mutation.
    Teofili L; Martini M; Cenci T; Petrucci G; Torti L; Storti S; Guidi F; Leone G; Larocca LM
    Blood; 2007 Jul; 110(1):354-9. PubMed ID: 17376889
    [TBL] [Abstract][Full Text] [Related]  

  • 73. JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia.
    Li J; Spensberger D; Ahn JS; Anand S; Beer PA; Ghevaert C; Chen E; Forrai A; Scott LM; Ferreira R; Campbell PJ; Watson SP; Liu P; Erber WN; Huntly BJ; Ottersbach K; Green AR
    Blood; 2010 Sep; 116(9):1528-38. PubMed ID: 20489053
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Quantitative determination of JAK2 V617F by TaqMan: An absolute measure of averaged copies per cell that may be associated with the different types of myeloproliferative disorders.
    Hammond E; Shaw K; Carnley B; P'ng S; James I; Herrmann R
    J Mol Diagn; 2007 Apr; 9(2):242-8. PubMed ID: 17384217
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Essential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2(V617F) in mice.
    Walz C; Ahmed W; Lazarides K; Betancur M; Patel N; Hennighausen L; Zaleskas VM; Van Etten RA
    Blood; 2012 Apr; 119(15):3550-60. PubMed ID: 22234689
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Essential thrombocythemia. Contribution of the V617F JAK2 mutation to the pathophysiology, diagnosis and outcome].
    Brière J
    Bull Acad Natl Med; 2007 Mar; 191(3):535-48. PubMed ID: 18072652
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Factors related to the development of acquired von Willebrand syndrome in patients with essential thrombocythemia and polycythemia vera.
    Rottenstreich A; Kleinstern G; Krichevsky S; Varon D; Lavie D; Kalish Y
    Eur J Intern Med; 2017 Jun; 41():49-54. PubMed ID: 27919526
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The myeloproliferative disorder-associated JAK2 V617F mutant escapes negative regulation by suppressor of cytokine signaling 3.
    Hookham MB; Elliott J; Suessmuth Y; Staerk J; Ward AC; Vainchenker W; Percy MJ; McMullin MF; Constantinescu SN; Johnston JA
    Blood; 2007 Jun; 109(11):4924-9. PubMed ID: 17317861
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Open-label study of oral CEP-701 (lestaurtinib) in patients with polycythaemia vera or essential thrombocythaemia with JAK2-V617F mutation.
    Hexner E; Roboz G; Hoffman R; Luger S; Mascarenhas J; Carroll M; Clementi R; Bensen-Kennedy D; Moliterno A
    Br J Haematol; 2014 Jan; 164(1):83-93. PubMed ID: 24903629
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Proinflammatory phenotype of iPS cell-derived JAK2 V617F megakaryocytes induces fibrosis in 3D in vitro bone marrow niche.
    Flosdorf N; Böhnke J; de Toledo MAS; Lutterbach N; Lerma VG; Graßhoff M; Olschok K; Gupta S; Tharmapalan V; Schmitz S; Götz K; Schüler HM; Maurer A; Sontag S; Küstermann C; Seré K; Wagner W; Costa IG; Brümmendorf TH; Koschmieder S; Chatain N; Castilho M; Schneider RK; Zenke M
    Stem Cell Reports; 2024 Feb; 19(2):224-238. PubMed ID: 38278152
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.